Table 1 Baseline characteristics according to outcome
Characteristic | All patients (N = 256) | Without remission (N = 103) | Remission (N = 153) | P value |
|---|---|---|---|---|
Demographics | ||||
Age, year | 49 (40–56) | 50 (40–57) | 49 (38–56) | 0.276 |
Male sex, no. (%) | 103 (40.2) | 36 (34.9) | 67 (43.7) | 0.157 |
Ethnicity | ||||
Asian | 256 (100) | 103 (100) | 153 (100) | > 0.99 |
Medical history | ||||
Hypertension, no. (%) | 46 (18) | 16 (16.5) | 30 (19.6) | 0.405 |
Diabetes, no. (%) | 17 (6.6) | 9 (8.7) | 8 (5.2) | 0.269 |
Anthropometric measurements | ||||
Systolic BP, mm Hg | 130 (118–140) | 126 (116–138) | 130 (120–144) | 0.008** |
Diastolic BP, mm Hg | 82 (75–90) | 79 (75–87) | 83 (76–92) | 0.026* |
BMI, kg/m2 | 24.2 (22.4–27.1) | 24.2 (21.7–26.8) | 24.3 (22.4–27.3) | 0.496 |
Kidney function measurements | ||||
Serum creatinine, μmol/L | 79 (63–99) | 83 (63–100) | 77 (62–99) | 0.606 |
Urine protein, g/d | 4.3 (2.3–7.2) | 3.8 (2.3–6.2) | 4.5 (2.7–7.6) | 0.086 |
Albumin, g/L | 26.9 (22.6–32.7) | 26.7 (21.9–30.7) | 27.8 (24.1–33.9) | 0.047* |
Plasma lipid levels | ||||
TC, mmol/L | 6.59 (5.25–8.19) | 7.13 (5.56–8.49) | 6.20 (4.99–7.89) | 0.011* |
Non-HDL-C, mmol/L | 5.12 (3.90–6.76) | 5.84 (4.13–7.17) | 4.92 (3.73–6.43) | 0.027* |
HDL-C, mmol/L | 1.28 (1.04–1.63) | 1.29 (1.05–1.62) | 1.28 (1.04–1.63) | 0.927 |
LDL-C, mmol/L | 3.73 (2.64–5.20) | 4.01 (2.96–5.87) | 3.49 (2.55–5.00) | 0.02* |
Triglyceride, mmol/L Medications | 2.23 (1.49–3.59) | 2.18 (1.56–3.27) | 2.28 (1.41–3.66) | 0.926 |
RAS blockade, no. (%) | 242 (94.5) | 96 (93.2%) | 146 (95.4) | 0.577 |
Steroid and immunosuppressant, no. (%) | 173 (67.6) | 65 (63.1) | 108 (70.6) | 0.210 |